https://transmembranetransport....ersinhibitor.com/ind
We report our early knowledge about a cohort of patients who had been in a position to proceed to allogeneic hematopoietic mobile transplantation (alloHCT) after HMA-VEN treatment. Thirty-two customers with AML (19 r/r and 13 de novo) with a median age 62 years underwent alloHCT after HMA-VEN treatment. Twenty-two (68.8%) were in full remission (CR)/CR with incomplete count recovery at period of HCT. With a median follow up of 14.4
Like
Comment
Share
